Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine

(Disponible en anglais seulement.)

Investigates the effects of two smokeless tobacco (ST) products (Exalt and Ariva) and a medicinal nicotine lozenge (MNL, Commit) on individuals who quit smoking. While low-nitrosamine ST products could reduce exposure to tobacco chemicals and lower the risk of disease, it is unclear how this product will be promoted to the general public as a harm reduction product.

http://dx.doi.org/10.1080/14622200701704228

Comment: Smokeless tobacco and harm reduction are current and divisive issues in tobacco control. It's encouraging to see that more research is being done in these areas.